Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144038 | 0.82 | CCNC (0.33) | — | |
| SCHEMBL4147779 | 0.69 | CYP2D6 (0.40) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4PIK3CD | |
| SCHEMBL18926689 | 0.65 | CYP2D6 (0.68) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4PIK3CD | |
| SCHEMBL3422977 | 0.64 | PIK3CD (0.47) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4PIK3CD | |
| SCHEMBL23866532 | 0.64 | CYP2D6 (0.44) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4PIK3CD | |
| SCHEMBL3422699 | 0.63 | CYP2D6 (0.50) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4PIK3CD | |
| SCHEMBL14706855 | 0.63 | CYP2D6 (0.66) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4PIK3CD | |
| SCHEMBL8881442 | 0.63 | CYP2D6 (0.50) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4PIK3CD | |
| SCHEMBL13703126 | 0.62 | OTUD7B (0.45) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4PIK3CD | |
| SCHEMBL25882686 | 0.62 | CYP2D6 (0.48) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | BETSCHART CLAUDIA | 2009-02-26 | — | — | US | disclosed |
| US-7452886-B2 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2008-11-18 | — | — | US | disclosed |
| EP-1423391-B8 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1423391-B1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2005-03-10 | — | — | US | disclosed |
| EP-1423391-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | CTSK, CTSS, CTSZ | CYP2D6 2419/4885SMN1; SMN2 4708/4885ALDH1A1 2931/4885 |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | CTSK, CTSS, CTSZ | CYP2D6 2419/4885SMN1; SMN2 4708/4885ALDH1A1 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.